High-dose chemotherapy in breast cancer -- the perils of history uncontrolled.

Kathy Miller, G. W. Sledge

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Breast cancer remains a common and devastating disease that affects approximately 180,000 women and results in more than 43,000 deaths annually in the United States. Although only 10% of patients have overt metastatic disease at the time of diagnosis, as many as one third of those who present with lymph node-negative disease and half of those who present with lymph node-positive disease eventually develop metastatic breast cancer. With few exceptions, metastatic breast cancer is largely incurable, and the median duration of survival remains 18 to 24 months. Over the past 3 decades, both laboratory and clinical efforts to increase survival have focused on dose intensity in chemotherapy regimens.

Original languageEnglish
JournalMedscape women's health
Volume5
Issue number3
StatePublished - 2000

Fingerprint

History
Breast Neoplasms
Drug Therapy
Lymph Nodes
Survival

Cite this

High-dose chemotherapy in breast cancer -- the perils of history uncontrolled. / Miller, Kathy; Sledge, G. W.

In: Medscape women's health, Vol. 5, No. 3, 2000.

Research output: Contribution to journalArticle

@article{9f02a933afa04a5aaad5ff167b49b5e2,
title = "High-dose chemotherapy in breast cancer -- the perils of history uncontrolled.",
abstract = "Breast cancer remains a common and devastating disease that affects approximately 180,000 women and results in more than 43,000 deaths annually in the United States. Although only 10{\%} of patients have overt metastatic disease at the time of diagnosis, as many as one third of those who present with lymph node-negative disease and half of those who present with lymph node-positive disease eventually develop metastatic breast cancer. With few exceptions, metastatic breast cancer is largely incurable, and the median duration of survival remains 18 to 24 months. Over the past 3 decades, both laboratory and clinical efforts to increase survival have focused on dose intensity in chemotherapy regimens.",
author = "Kathy Miller and Sledge, {G. W.}",
year = "2000",
language = "English",
volume = "5",
journal = "Medscape women's health",
issn = "1521-2076",
publisher = "Medscape Health Network",
number = "3",

}

TY - JOUR

T1 - High-dose chemotherapy in breast cancer -- the perils of history uncontrolled.

AU - Miller, Kathy

AU - Sledge, G. W.

PY - 2000

Y1 - 2000

N2 - Breast cancer remains a common and devastating disease that affects approximately 180,000 women and results in more than 43,000 deaths annually in the United States. Although only 10% of patients have overt metastatic disease at the time of diagnosis, as many as one third of those who present with lymph node-negative disease and half of those who present with lymph node-positive disease eventually develop metastatic breast cancer. With few exceptions, metastatic breast cancer is largely incurable, and the median duration of survival remains 18 to 24 months. Over the past 3 decades, both laboratory and clinical efforts to increase survival have focused on dose intensity in chemotherapy regimens.

AB - Breast cancer remains a common and devastating disease that affects approximately 180,000 women and results in more than 43,000 deaths annually in the United States. Although only 10% of patients have overt metastatic disease at the time of diagnosis, as many as one third of those who present with lymph node-negative disease and half of those who present with lymph node-positive disease eventually develop metastatic breast cancer. With few exceptions, metastatic breast cancer is largely incurable, and the median duration of survival remains 18 to 24 months. Over the past 3 decades, both laboratory and clinical efforts to increase survival have focused on dose intensity in chemotherapy regimens.

UR - http://www.scopus.com/inward/record.url?scp=0034178804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034178804&partnerID=8YFLogxK

M3 - Article

C2 - 11109042

AN - SCOPUS:0034178804

VL - 5

JO - Medscape women's health

JF - Medscape women's health

SN - 1521-2076

IS - 3

ER -